US Patent Issued to BLUEPRINT MEDICINES on June 30 for "Substituted pyrimidinyl-pyrazoles as CDK2 inhibitors" (Massachusetts Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,668,585, issued on June 30, was assigned to BLUEPRINT MEDICINES Corp. (Cambridge, Mass.).

"Substituted pyrimidinyl-pyrazoles as CDK2 inhibitors" was invented by Philip D. Ramsden (Cambridge, Mass.), Neil Bifulco Jr. (Sudbury, Mass.), Natasja Brooijmans (Boston), Emanuele Perola (Cambridge, Mass.), Richard Vargas (Cambridge, Mass.), Steven Mark Wenglowsky (Cambridge, Mass.) and Douglas Wilson (Ayer, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides a compound represented by structural formula (I): (I), or a pharmaceutically acceptable salt thereof useful for treating a cancer."

The patent was filed on June 15, 2022, un...